Syndax Pharmaceuticals(SNDX)
NEW YORK, NYPharmaceutical
Focus: Syndax Pharmaceuticals is a publicly traded oncology-focused company specializing in tumor phenotype modification with a lead commercial product (Revumenib) and a robust pipeline spanning breast cancer, leukemias, and solid tumors. The company operates as a mid-cap biotech with R&D intensity and a focused therapeutic portfolio.
Profile data last refreshed 3h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
9-7 this month
Cooling — net -7 jobs in 30d
4 added, 11 removed. Slower than typical.
Should You Work at Syndax Pharmaceuticals?
AI assessmentBest suited for oncology-focused scientists and clinical developers willing to accept pre-profitability volatility in exchange for deep pipeline exposure and early-stage drug ownership.
Why Work Here
- Public company with commercial execution underway: Revumenib (Revuforj) achieved NDA approval with LOE not until 2042, providing long-term revenue visibility.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$0K
Key Products
Growth16.1yr
First commercial product with 17-year LOE runway; backbone of revenue model and clinical development strategy.
Help build intelligence for Syndax Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.